<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31903">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064218</url>
  </required_header>
  <id_info>
    <org_study_id>20070002649</org_study_id>
    <nct_id>NCT02064218</nct_id>
  </id_info>
  <brief_title>Emerging Biomarkers in Hypertension</brief_title>
  <official_title>Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First of all to evaluate the relationship between non-conventional biomarkers and essential
      hypertension; then to evaluate the effects of various anti-hypertensive drugs on blood
      pressure control and non-conventional biomarkers in naive hypertensive patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Blood pressure reduction</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Systolic Blood Pressure (SBP)
Diastolic Blood Pressure (DBP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular and metabolic biomarkers</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lipoprotein (a) (Lp(a))
sRAGE (soluble Receptor for Advanced Glycation End-products)
sCD40L (soluble ligand of CD40)
MPO (myeloperoxidase)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of vascular stiffness</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>- Aortic Pulse Wave velocity (PWV)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Hypertensive patients</arm_group_label>
    <description>Hypertensive patients naive to hypertensive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects</arm_group_label>
    <description>healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-hypertensive drugs</intervention_name>
    <arm_group_label>Hypertensive patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with naive essential hypertension aged &lt; 65 years without previous cardiovascular
        events
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  essential hypertension

          -  naive to treatment

          -  &lt; 65 years

        Exclusion Criteria:

          -  secondary hypertension

          -  previous cardiovascular events
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Derosa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD, PhD</last_name>
    <phone>+39 0382 502614</phone>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amedeo Mugellini, MD, PhD</last_name>
    <phone>+39 0382 502614</phone>
    <email>amedeo.mugellini@unipv.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico S.Matteo Foundation</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD, PhD</last_name>
      <phone>+39 0382 502614</phone>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Pamela Maffioli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
